Hui Min Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hui Min Jin has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Xiu Hong Yang
Department of Nephrology, Huadong Hospital, Fudan University, Shanghai, China
22 shared publications- Xiu Hong Yang
Division of Nephrology, Shanghai Pudong Hospital, Pudong Medical Center, Fudan University, Shanghai, China
10 shared publications Bao Long Zhang
The Institutes of Biomedical Sciences (IBS), Fudan University
9 shared publicationsYan Hong Gu
Shanghai Pudong Hospital
8 shared publicationsYao Liu
Department of Nephrology, Huadong Hospital, Fudan University, Shanghai, China
7 shared publicationsYun Cheng
Department of Nephrology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center
7 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Springer Nature in Translational Psychiatry
Association of urine albumin-to-creatinine ratio (UACR) with risks of incident depression and anxiety in adults: A prospective cohort study
- 15 September 2026
- Published by Springer Nature in Translational Psychiatry
Open AccessAssociation of urine albumin-to-creatinine ratio (UACR) with risks of incident depression and anxiety in adults: A prospective cohort study
- Open Access
- 9 July 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1868198
Therapeutic monoclonal antibodies for diabetic kidney disease: a narrative review from basic mechanisms to clinical evidence
Introduction: Diabetic kidney disease (DKD) remains a leading cause of end-stage kidney disease despite advances with renin–angiotensin system blockade, sodium–glucose cotransporter 2 inhibitors, finerenone, and glucagon-like peptide-1 receptor agonists. Therapeutic monoclonal antibodies may offer a targeted strategy to modulate inflammatory, fibrotic, metabolic, and vascular pathways involved in DKD. This review summarizes the mechanistic rationale, clinical evidence, translational barriers, and future prospects of antibody-based therapies for DKD. Methods: We conducted a narrative literature review using PubMed, the Cochrane Library, and ClinicalTrials.gov from database inception to March 31, 2026. We prioritized peer-reviewed preclinical studies, clinical trials, and high-quality reviews addressing mAb-based strategies targeting DKD-related pathways, including TGF-β1, VEGF-B, CTGF, suPAR, integrin αvβ8, signal regulatory protein α, and PCSK9. Results: Phase II studies of anti-TGF-β1 and anti-VEGF-B antibodies failed to show meaningful renal benefit, highlighting challenges such as pathway redundancy, delayed intervention, insufficient intrarenal target engagement, and off-kidney toxicity. Anti-CTGF therapy showed an early signal of albuminuria, whereas anti-suPAR remains under clinical evaluation. Emerging preclinical targets, including integrin αvβ8 and signal regulatory protein α, may provide more kidney-focused modulation of fibrotic and inflammatory pathways. PCSK9 monoclonal antibodies, particularly evolocumab and alirocumab, appear promising because they may confer renal benefit through lipid lowering and kidney-intrinsic effects on lipotoxicity, oxidative stress, AMPK signaling, and profibrotic pathways. Conclusion: Monoclonal antibodies represent a biologically compelling but clinically underdeveloped strategy for DKD. Future progress will require earlier biomarker-informed patient selection, confirmation of intrarenal target engagement, appropriate renal endpoints, and rational combination with established kidney-protective therapies.
- 9 July 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1868198
Open AccessTherapeutic monoclonal antibodies for diabetic kidney disease: a narrative review from basic mechanisms to clinical evidence
Introduction: Diabetic kidney disease (DKD) remains a leading cause of end-stage kidney disease despite advances with renin–angiotensin system blockade, sodium–glucose cotransporter 2 inhibitors, finerenone, and glucagon-like peptide-1 receptor agonists. Therapeutic monoclonal antibodies may offer a targeted strategy to modulate inflammatory, fibrotic, metabolic, and vascular pathways involved in DKD. This review summarizes the mechanistic rationale, clinical evidence, translational barriers, and future prospects of antibody-based therapies for DKD. Methods: We conducted a narrative literature review using PubMed, the Cochrane Library, and ClinicalTrials.gov from database inception to March 31, 2026. We prioritized peer-reviewed preclinical studies, clinical trials, and high-quality reviews addressing mAb-based strategies targeting DKD-related pathways, including TGF-β1, VEGF-B, CTGF, suPAR, integrin αvβ8, signal regulatory protein α, and PCSK9. Results: Phase II studies of anti-TGF-β1 and anti-VEGF-B antibodies failed to show meaningful renal benefit, highlighting challenges such as pathway redundancy, delayed intervention, insufficient intrarenal target engagement, and off-kidney toxicity. Anti-CTGF therapy showed an early signal of albuminuria, whereas anti-suPAR remains under clinical evaluation. Emerging preclinical targets, including integrin αvβ8 and signal regulatory protein α, may provide more kidney-focused modulation of fibrotic and inflammatory pathways. PCSK9 monoclonal antibodies, particularly evolocumab and alirocumab, appear promising because they may confer renal benefit through lipid lowering and kidney-intrinsic effects on lipotoxicity, oxidative stress, AMPK signaling, and profibrotic pathways. Conclusion: Monoclonal antibodies represent a biologically compelling but clinically underdeveloped strategy for DKD. Future progress will require earlier biomarker-informed patient selection, confirmation of intrarenal target engagement, appropriate renal endpoints, and rational combination with established kidney-protective therapies.
- Open Access
- 11 June 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1873856
Normal serum uric acid gout: a neglected and challenging condition
During acute gout flares, serum uric acid (SUA) levels may remain within the normal range, making diagnosis based solely on SUA unreliable. A systematic evaluation incorporating clinical symptoms and imaging (ultrasound, dual-source CT) is essential to detect monosodium urate (MSU) crystal deposition. Normal-SUA gout often presents with more pronounced inflammation, fever, elevated white blood cell count and C-reactive protein, and may occur after surgery or hemodialysis. Tophi can appear at typical or atypical sites (e.g., face, neck). No specific treatment guidelines exist, but lowering SUA to <360 μmol/L (6 mg/dl) reduces gout flares and promotes MSU dissolution. Emerging therapies—including anti-IL-1β monoclonal antibodies, NLRP3 inhibitors, uricases, and green tea components—show promise in controlling attacks and dissolving crystals without affecting SUA levels.
- 11 June 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1873856
Open AccessNormal serum uric acid gout: a neglected and challenging condition
During acute gout flares, serum uric acid (SUA) levels may remain within the normal range, making diagnosis based solely on SUA unreliable. A systematic evaluation incorporating clinical symptoms and imaging (ultrasound, dual-source CT) is essential to detect monosodium urate (MSU) crystal deposition. Normal-SUA gout often presents with more pronounced inflammation, fever, elevated white blood cell count and C-reactive protein, and may occur after surgery or hemodialysis. Tophi can appear at typical or atypical sites (e.g., face, neck). No specific treatment guidelines exist, but lowering SUA to <360 μmol/L (6 mg/dl) reduces gout flares and promotes MSU dissolution. Emerging therapies—including anti-IL-1β monoclonal antibodies, NLRP3 inhibitors, uricases, and green tea components—show promise in controlling attacks and dissolving crystals without affecting SUA levels.
- 16 April 2026
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 236, 113265
Urinary albumin-to-creatinine ratio and incident type 2 diabetes: a 13.8-year cohort study of 411,389 UK biobank participants
- 16 April 2026
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 236, 113265
Urinary albumin-to-creatinine ratio and incident type 2 diabetes: a 13.8-year cohort study of 411,389 UK biobank participants
- Open Access
- 15 January 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (1)
Urine albumin-to-creatinine ratio and risks of incident arterial thromboembolism and pulmonary embolism among adults—a prospective cohort study
- 15 January 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (1)
Open AccessUrine albumin-to-creatinine ratio and risks of incident arterial thromboembolism and pulmonary embolism among adults—a prospective cohort study
- 21 March 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 223, 112106
Reply to “Daytime napping and risk of incident main adverse cardiovascular events and mortality among adults with type 2 diabetes”
- 21 March 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 223, 112106
Reply to “Daytime napping and risk of incident main adverse cardiovascular events and mortality among adults with type 2 diabetes”
- Top Cited PapersOpen Access
- 18 March 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1503711
Lipid abnormality in diabetic kidney disease and potential treatment advancements
Numerous studies have shown that dyslipidemia increases the risk of atherosclerotic cardiovascular disease (ASCVD) and significantly impacts the occurrence and progression of diabetic kidney disease (DKD). Early interventions for lipid metabolism disorders in DKD may improve renal function. This article reviews the clinical characteristics of dyslipidemia, mechanisms of lipid-induced renal injury, and advances in lipid-lowering therapy in DKD. We searched PubMed, Web of Science, and EMBASE to identify relevant articles, using keywords such as “diabetic kidney disease”, “diabetic nephropathy”, “diabetes”, “dyslipidemia”, “kidney”, “cardiovascular disease”, and “lipid therapy”. High triglyceride (TG) and low high-density lipoprotein (HDL) are associated with increased risks of albuminuria and estimated glomerular filtration rate (eGFR) decline. Abnormal lipid metabolism may damage glomerular podocytes and renal tubular epithelial cells via ectopic lipid deposition, eventually impairing glomerular filtration function and increasing urinary albumin excretion. Lipid-lowering therapies can ameliorate lipid accumulation, downregulate inflammatory mediator expressions, and alleviate renal fibrosis. Fibrate and statin applications exhibit beneficial effects, reducing albuminuria and slowing eGFR decline in early DKD. However, the long-term effects of statins and fibrates on renal outcomes remain controversial. Pro-protein convertase subtilisin/kexin 9 (PCSK9)-targeted interventions have minimal side effects on the kidneys and seem effective in reducing inflammation and improving renal impairment compared with statins and fibrates. In addition, LDL apheresis (LDL-A) and double filtration plasmapheresis (DFPP) are promising clinical applications in diabetic patients with severe hypercholesterolemia or lipid-lowering drug intolerance.
- 18 March 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1503711
Top Cited PapersOpen AccessLipid abnormality in diabetic kidney disease and potential treatment advancements
Numerous studies have shown that dyslipidemia increases the risk of atherosclerotic cardiovascular disease (ASCVD) and significantly impacts the occurrence and progression of diabetic kidney disease (DKD). Early interventions for lipid metabolism disorders in DKD may improve renal function. This article reviews the clinical characteristics of dyslipidemia, mechanisms of lipid-induced renal injury, and advances in lipid-lowering therapy in DKD. We searched PubMed, Web of Science, and EMBASE to identify relevant articles, using keywords such as “diabetic kidney disease”, “diabetic nephropathy”, “diabetes”, “dyslipidemia”, “kidney”, “cardiovascular disease”, and “lipid therapy”. High triglyceride (TG) and low high-density lipoprotein (HDL) are associated with increased risks of albuminuria and estimated glomerular filtration rate (eGFR) decline. Abnormal lipid metabolism may damage glomerular podocytes and renal tubular epithelial cells via ectopic lipid deposition, eventually impairing glomerular filtration function and increasing urinary albumin excretion. Lipid-lowering therapies can ameliorate lipid accumulation, downregulate inflammatory mediator expressions, and alleviate renal fibrosis. Fibrate and statin applications exhibit beneficial effects, reducing albuminuria and slowing eGFR decline in early DKD. However, the long-term effects of statins and fibrates on renal outcomes remain controversial. Pro-protein convertase subtilisin/kexin 9 (PCSK9)-targeted interventions have minimal side effects on the kidneys and seem effective in reducing inflammation and improving renal impairment compared with statins and fibrates. In addition, LDL apheresis (LDL-A) and double filtration plasmapheresis (DFPP) are promising clinical applications in diabetic patients with severe hypercholesterolemia or lipid-lowering drug intolerance.
- 25 February 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 222, 112067
Daytime napping and risk of incident main adverse cardiovascular events and mortality among adults with type 2 diabetes
- 25 February 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 222, 112067
Daytime napping and risk of incident main adverse cardiovascular events and mortality among adults with type 2 diabetes
- Open Access
- 11 February 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-13
Association of aberrant mineral metabolic markers with fracture risk in chronic kidney disease: a comprehensive meta-analysis
This meta-analysis aims to investigate the impact of abnormalities in mineral metabolic markers, including serum phosphate and calcium, intact parathyroid hormone (iPTH), and fibroblast growth factor 23 (FGF23) on the risk of fractures in patients with chronic kidney disease (CKD). A systematic search was conducted across MEDLINE, Web of Science, EMBASE, ClinicalTrials.gov, and the Cochrane Central Register for Controlled Trials. The outcomes were association of mineral metabolic markers with the risk of fractures in patients with chronic kidney disease. Pooled risk estimates and 95% confidence intervals (CIs) were calculated using fixed-effects or random-effects models. Thirty-two studies were included in the meta-analysis. High and low levels of serum phosphate in hemodialysis (HD) patients were both associated with an increased risk of fractures (RR = 1.08, 95% CI 1.02–1.15, P = 0.013; RR = 1.13, 95% CI 1.02–1.25, P = 0.022, respectively). Similarly, abnormal levels of iPTH in CKD patients, both high and low, were associated with increased fracture risk (RR = 1.25, 95% CI 1.20–1.31, P < 0.001; RR = 1.41, 95% CI 1.10–1.82, P = 0.007, respectively). Elevated FGF23 levels were also linked to an increased risk of fractures (RR = 1.32, 95% CI 1.06–1.66, P = 0.015). While a higher level of calcium exhibited a trend towards reduced fracture incidence without statistical significance (RR = 0.90, 95% CI 0.77–1.05, P = 0.181), lower calcium levels tended to increase fracture risk without statistical significance (RR = 1.11, 95% CI 0.99–1.24, P = 0.087). Notably, subjects treated with calcium and phosphorus modulating drugs demonstrated a statistically significant reduction in fractures among CKD patients undergoing dialysis (phosphate binders, RR = 0.79, 95% CI 0.70–0.89; cinacalcet, RR = 0.74, 95% CI 0.59–0.93; vitamin D analogues, RR = 0.82, 95% CI 0.74–0.92, respectively). This meta-analysis underscores the association between abnormal mineral metabolic markers, including high serum phosphate, iPTH, and FGF23, and an increased risk of fractures in CKD patients. Notably, both elevated and decreased levels of phosphate and iPTH contribute to fracture risk. The efficacy of active vitamin D, phosphorus binders, and cinacalcet in preventing fractures was observed in HD patients but not in the non-dialysis CKD population. PROSPERO CRD42023493951.
- 11 February 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-13
Open AccessAssociation of aberrant mineral metabolic markers with fracture risk in chronic kidney disease: a comprehensive meta-analysis
This meta-analysis aims to investigate the impact of abnormalities in mineral metabolic markers, including serum phosphate and calcium, intact parathyroid hormone (iPTH), and fibroblast growth factor 23 (FGF23) on the risk of fractures in patients with chronic kidney disease (CKD). A systematic search was conducted across MEDLINE, Web of Science, EMBASE, ClinicalTrials.gov, and the Cochrane Central Register for Controlled Trials. The outcomes were association of mineral metabolic markers with the risk of fractures in patients with chronic kidney disease. Pooled risk estimates and 95% confidence intervals (CIs) were calculated using fixed-effects or random-effects models. Thirty-two studies were included in the meta-analysis. High and low levels of serum phosphate in hemodialysis (HD) patients were both associated with an increased risk of fractures (RR = 1.08, 95% CI 1.02–1.15, P = 0.013; RR = 1.13, 95% CI 1.02–1.25, P = 0.022, respectively). Similarly, abnormal levels of iPTH in CKD patients, both high and low, were associated with increased fracture risk (RR = 1.25, 95% CI 1.20–1.31, P < 0.001; RR = 1.41, 95% CI 1.10–1.82, P = 0.007, respectively). Elevated FGF23 levels were also linked to an increased risk of fractures (RR = 1.32, 95% CI 1.06–1.66, P = 0.015). While a higher level of calcium exhibited a trend towards reduced fracture incidence without statistical significance (RR = 0.90, 95% CI 0.77–1.05, P = 0.181), lower calcium levels tended to increase fracture risk without statistical significance (RR = 1.11, 95% CI 0.99–1.24, P = 0.087). Notably, subjects treated with calcium and phosphorus modulating drugs demonstrated a statistically significant reduction in fractures among CKD patients undergoing dialysis (phosphate binders, RR = 0.79, 95% CI 0.70–0.89; cinacalcet, RR = 0.74, 95% CI 0.59–0.93; vitamin D analogues, RR = 0.82, 95% CI 0.74–0.92, respectively). This meta-analysis underscores the association between abnormal mineral metabolic markers, including high serum phosphate, iPTH, and FGF23, and an increased risk of fractures in CKD patients. Notably, both elevated and decreased levels of phosphate and iPTH contribute to fracture risk. The efficacy of active vitamin D, phosphorus binders, and cinacalcet in preventing fractures was observed in HD patients but not in the non-dialysis CKD population. PROSPERO CRD42023493951.
- Open Access
- 13 May 2024
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2332956
Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials
It is unknown whether febuxostat can delay the progression of kidney dysfunction and reduce kidney endpoint events. The aim was to evaluate the renoprotective effect of febuxostat in patients with hyperuricemia or gout by performing a meta-analysis of randomized controlled trials (RCTs). MEDLINE, Web of science, EMBASE, ClinicalTrials.gov, and the Cochrane Central Register for Randomized Controlled Trials were searched. The main outcomes included kidney events (serum creatinine doubling or progression to end-stage kidney disease or dialysis). The secondary outcomes were the rate of change in the estimated glomerular filtration rate (eGFR) and changes in the urine protein or urine albumin to creatinine ratio from baseline to the end of follow-up. We used random-effects models to calculate the pooled risk estimates and 95% CIs. A total of 16 RCTs were included in the meta-analysis. In comparison with the control group, the patients who received febuxostat showed a reduced risk of kidney events (RR = 0.56, 95% CI 0.37–0.84, p = 0.006) and a slower decline in eGFR (WMD = 0.90 mL/min/1.73 m2, 95% CI 0.31–1.48, p = 0.003). The pooled results also revealed that febuxostat use reduced the urine albumin to creatinine ratio (SMD = −0.21, 95% CI −0.41 to −0.01, p = 0.042). Febuxostat use is associated with a reduced risk of kidney events and a slow decline in eGFR. In addition, the urine albumin to creatinine ratio decreased in febuxostat users. Accordingly, it is an effective drug for delaying the progression of kidney function deterioration in patients with gout. Systematic review registration: PROSPERO CRD42021272591
- 13 May 2024
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2332956
Open AccessFebuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials
It is unknown whether febuxostat can delay the progression of kidney dysfunction and reduce kidney endpoint events. The aim was to evaluate the renoprotective effect of febuxostat in patients with hyperuricemia or gout by performing a meta-analysis of randomized controlled trials (RCTs). MEDLINE, Web of science, EMBASE, ClinicalTrials.gov, and the Cochrane Central Register for Randomized Controlled Trials were searched. The main outcomes included kidney events (serum creatinine doubling or progression to end-stage kidney disease or dialysis). The secondary outcomes were the rate of change in the estimated glomerular filtration rate (eGFR) and changes in the urine protein or urine albumin to creatinine ratio from baseline to the end of follow-up. We used random-effects models to calculate the pooled risk estimates and 95% CIs. A total of 16 RCTs were included in the meta-analysis. In comparison with the control group, the patients who received febuxostat showed a reduced risk of kidney events (RR = 0.56, 95% CI 0.37–0.84, p = 0.006) and a slower decline in eGFR (WMD = 0.90 mL/min/1.73 m2, 95% CI 0.31–1.48, p = 0.003). The pooled results also revealed that febuxostat use reduced the urine albumin to creatinine ratio (SMD = −0.21, 95% CI −0.41 to −0.01, p = 0.042). Febuxostat use is associated with a reduced risk of kidney events and a slow decline in eGFR. In addition, the urine albumin to creatinine ratio decreased in febuxostat users. Accordingly, it is an effective drug for delaying the progression of kidney function deterioration in patients with gout. Systematic review registration: PROSPERO CRD42021272591